Drotaverine in Dysmenorrhoea Treatment

Inclusion Criteria: * History of at least 6 months of dysmenorrhea, with presence of moderate to severe pain in each of the last 3 cycles * With regular menstrual cycles (25-35 days) * Using an adequate barrier contraception method (except for virgins) Exclusion Criteria: * Evidence of clinically relevant gynecological, cardiovascular, hematologic, hepatic, gastrointestinal, renal, pulmonary, endocrinologic, neurologic or psychiatric disease, based on a clinical assessment and routine laboratory investigations * Proven hypersensitivity to drotaverine hydrochloride or ibuprofen or proven intolerance to lactose * Any described contraindication to either drotaverine hydrochloride or ibuprofen (see Summary of Product Characteristics) * Oestro-progestative contraception within the last 2 months * Regular use of sedative, hypnotics, tranquillizers or any other addictive agents * History or evidence of acute or chronic alcohol abuse * Heavy smoking (\> 10 cigarettes/day) * Need of a permanent treatment with other antispasmodics and/or analgesic agents during the trial * Lactation * Pregnancy * Participation in another clinical trial in the last 3 months prior to the start of this study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.